Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncologyVincenzo Quagliariello, Nicola Maurea, Domenico Gabrielli et al.|Frontiers in Cardiovascular Medicine|2024Cited by 16
SGLT2i Dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicityNicola Maurea, Vincenzo Quagliariello, Maria Laura Canale et al.|European Heart Journal|2023Cited by 3
SGLT2 i Dapagliflozin reduces NF-kB expression in heart and kydneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways: an hystological studyNicola Maurea, Vincenzo Quagliariello, Isabella Bisceglia et al.|European Heart Journal|2023Cited by 2
P173 THERAPEUTIC MANAGEMENT OF FLUOROPYRIMIDINE CARDIOTOXICITY: AN ANECDOTAL CASEAndrea Paccone, Nicola Maurea, Isabella Bisceglia et al.|European Heart Journal Supplements|2023Cited by 1
Dapagliflozin improves radial and longitudinal strain, increases pAMPK and reduces myocardial and renal NF-kB expression in preclinical models of doxorubicin cardiotoxicity through NLRP3 and Myd-88Nicola Maurea, Vincenzo Quagliariello, Maria Laura Canale et al.|European Heart Journal - Cardiovascular Imaging|2023Cited by 1